drugset / Trial / NCT00415246

Study to Evaluate a Subcutaneous Four Months Sustained-release Formulation of Triptorelin in Patients With Prostate Cancer

NCT00415246

Phase 3 Terminated 100 enrolled Ipsen
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To identify the proportion of patients remaining medically castrated (testosterone level \< 50 ng/dL) on Day 240 following two administrations of a 4-month sustained-release (SR) formulation of triptorelin.

Timeline

Start
2006-11
Primary completion
Completion
2007-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified

Indications